Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.
Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.
Anticoagulation reduced adverse clinical events in patients with atrial fibrillation at intermediate stroke risk, without an ...
Over a median follow-up of 210.1 weeks, tirzepatide was found to be noninferior to dulaglutide, with an 8% lower rate of MACE-3. The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI, 0 ...
Visible hyperpigmentation may mask persistent erythema and should not be assumed to indicate resolved inflammation,’ ...
A novel ultrasound-derived score combined with liver stiffness measurement can identify both MASH and fibrosis, potentially ...
The assay’s significant limitation is its inability to assess drug resistance for integrase inhibitors, including ...
In a phase 3 trial, adding a combo of two traditional Chinese meds to metformin reduced A1c and improved lipid measure in ...
Among adult veterans, oseltamivir treatment initiated within 6 hours of influenza diagnosis is associated with a reduced risk ...
Antiviral treatment started within 48 hours of symptom onset is linked to a reduced risk for hospitalization among pediatric ...
Laser interstitial thermal therapy (LITT) demonstrates low complication rates in a study of nearly 800 patients with brain ...
The FDA has approved brepocitinib (Lisraya), an oral JAK inhibitor, for the treatment of dermatomyositis, a rare autoimmune ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results